Crossmark Global Holdings Inc. Has $174,000 Holdings in R1 RCM Inc. (NASDAQ:RCM)

Crossmark Global Holdings Inc. trimmed its position in shares of R1 RCM Inc. (NASDAQ:RCM) by 49.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 12,254 shares of the healthcare provider’s stock after selling 12,000 shares during the period. Crossmark Global Holdings Inc.’s holdings in R1 RCM were worth $174,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. QRG Capital Management Inc. bought a new stake in R1 RCM in the first quarter worth $132,000. Clearbridge Investments LLC increased its holdings in shares of R1 RCM by 16.9% during the 1st quarter. Clearbridge Investments LLC now owns 1,162,703 shares of the healthcare provider’s stock valued at $14,976,000 after acquiring an additional 168,197 shares during the last quarter. Natixis bought a new position in shares of R1 RCM in the 1st quarter valued at approximately $2,883,000. Advisors Asset Management Inc. acquired a new stake in R1 RCM in the 1st quarter worth approximately $27,000. Finally, Gabelli Funds LLC bought a new stake in R1 RCM during the first quarter worth approximately $2,114,000. Institutional investors own 61.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on RCM shares. TD Cowen restated a “hold” rating and issued a $14.30 price objective (down from $20.00) on shares of R1 RCM in a research note on Monday, August 5th. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 target price on shares of R1 RCM in a research report on Monday, July 22nd. Leerink Partners lowered R1 RCM from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $17.00 to $14.30 in a research note on Thursday, August 1st. Morgan Stanley downgraded R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 8th. Finally, Leerink Partnrs downgraded R1 RCM from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Thirteen research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $15.41.

R1 RCM Stock Up 0.1 %

NASDAQ RCM opened at $14.31 on Tuesday. R1 RCM Inc. has a 1-year low of $8.87 and a 1-year high of $15.12. The company has a market capitalization of $6.04 billion, a price-to-earnings ratio of -95.39 and a beta of 0.84. The stock’s 50 day moving average is $14.22 and its two-hundred day moving average is $13.42. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.76.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Tuesday, November 5th. The healthcare provider reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.04). R1 RCM had a negative return on equity of 2.18% and a negative net margin of 2.48%. The company had revenue of $656.80 million for the quarter, compared to analyst estimates of $640.93 million. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. Equities analysts forecast that R1 RCM Inc. will post -0.38 earnings per share for the current fiscal year.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.